Orion Oyj (OTCMKTS:ORINY) Short Interest Update

Orion Oyj (OTCMKTS:ORINY - Get Free Report) was the recipient of a large decline in short interest in October. As of October 15th, there was short interest totalling 100 shares, a decline of 66.7% from the September 30th total of 300 shares. Based on an average daily volume of 100 shares, the days-to-cover ratio is currently 1.0 days.

Orion Oyj Price Performance

Shares of Orion Oyj stock traded down $1.14 on Friday, hitting $24.26. The company's stock had a trading volume of 103 shares, compared to its average volume of 500. Orion Oyj has a 1 year low of $17.50 and a 1 year high of $28.55. The company has a market capitalization of $6.85 billion, a price-to-earnings ratio of 27.89 and a beta of 0.21. The company has a debt-to-equity ratio of 0.31, a quick ratio of 1.29 and a current ratio of 2.39. The firm has a fifty day moving average price of $26.68 and a 200-day moving average price of $22.64.

Orion Oyj (OTCMKTS:ORINY - Get Free Report) last announced its earnings results on Thursday, August 8th. The company reported $0.17 earnings per share (EPS) for the quarter. Orion Oyj had a net margin of 18.08% and a return on equity of 27.97%. The business had revenue of $332.07 million for the quarter. As a group, sell-side analysts anticipate that Orion Oyj will post 1.26 earnings per share for the current fiscal year.

Orion Oyj Cuts Dividend

The company also recently declared a dividend, which will be paid on Thursday, November 7th. Investors of record on Wednesday, October 16th will be given a dividend of $0.2405 per share. The ex-dividend date of this dividend is Wednesday, October 16th. Orion Oyj's payout ratio is 40.23%.

Orion Oyj Company Profile

Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, rest of Europe, North America, and internationally. The company provides prescription drugs and self-care products, which includes Nubeqa for the treatment of prostate cancer; Precedex, Dexdor, and Precedex for human use; Burana for inflammatory pain; Divina series for menopausal symptoms; Trexan for rheumatoid arthritis and cancer; Stalevo, Entacapone, and Comtess/Comtan for Parkinson's disease; Biosimilars for rheumatoid arthritis and inflammatory bowel diseases; and Simdax for acute decompensated heart failure, as well as Fareston for breast cancer.